NCT01564875View on ClinicalTrials.gov

Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia

PHASE4UnknownINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Chronic Kidney DiseaseHyperlipidemia
Interventions
DRUG

Simvast CR

Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.

DRUG

Zocor

Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.

Trial Locations (7)

Unknown

Hallym University Medical Center, Anyang-si

Inje University Ilsan Paik Hospital, Goyang-si

Gachon University Gil Hospital, Incheon

Eulji General Hospital, Seoul

Hanyang University Seoul Hospital, Seoul

Korea University Anam Hospital, Seoul

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01564875 - Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia | Biotech Hunter | Biotech Hunter